JP Morgan Chase
DNTH icon

JP Morgan Chase’s Dianthus Therapeutics DNTH Stock Holding History

JP Morgan Chase’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,300
Closed -$183K – 7814
2026
Q1 		$183K Buy
+2,300
New +$133K ﹤0.01% 5518

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

JP Morgan Chase's DNTH Position: Q2 2026 in Review

JP Morgan Chase reduced its Dianthus Therapeutics (DNTH) stake by 0.49% in Q2 2026, selling an estimated $13.5K and leaving 31,783 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3831.

JP Morgan Chase first reported a position in DNTH in Q3 2018 and has held it in 32 quarters since. The position peaked at $5.59M in Q1 2021. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • JP Morgan Chase held 31,783 shares of Dianthus Therapeutics worth $3.21M as of Q2 2026.
  • JP Morgan Chase sold 155 Dianthus Therapeutics shares in Q2 2026, an estimated $13.5K.
  • Dianthus Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3831 holding.
  • JP Morgan Chase first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 32 quarters since.
  • JP Morgan Chase's Dianthus Therapeutics position peaked at $5.59M in Q1 2021.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.